Stay informed. Stay inspired. Stay connected- directly with Robert Weber

The Weber Light Letter: Issue No. 1

From studies to practice: The latest in tPBM and laser therapy for clinicians

Welcome to the Newsletter

For over 20 years, my work has been dedicated to one question: How can we safely and effectively use light to support healing?

Through my clinical research, device development at Weber Medical, and collaborations with doctors worldwide, I’ve seen how photobiomodulation (PBM) and minimally invasive laser therapies are moving from experimental to essential.

This newsletter is a space where I’ll share:

• The latest research on PBM and regenerative medicine
• Clinical cases and protocols from ongoing practice
• News and trends in the global light therapy field

My goal is simple: to provide clinicians with timely, credible, and practical insights you can bring into your own work.

Why Light Therapy is Gaining Momentum

Transcranial photobiomodulation (tPBM) directs near-infrared light through the skull to reach cortical and subcortical structures. By stimulating cytochrome c oxidase in mitochondria, it boosts ATP production, improves cerebral blood flow, and reduces neuroinflammation.

Recent clinical studies have shown measurable improvements in:

• Alzheimer’s & Parkinson’s – better cognitive performance and slowed decline
• Post-stroke rehab – improved motor recovery and neuroplasticity
• Long-COVID – reduced brain fog and fatigue, improved daily function

📑 Hamblin MR, “Transcranial Photobiomodulation and Brain Health,” Cells, 2024 (link)

Clinical takeaway: tPBM works at the cellular level and can be applied across multiple neurological disorders.

Next step: Identify patient groups in your practice that could benefit from a safe, non-invasive therapy for energy, cognition, and recovery.

Pain Studies: Evidence You Can Use

Light isn’t only for neurological recovery, it has strong evidence in pain management as well.

• A 2024 clinical study on intravascular laser therapy (ILIB) in knee osteoarthritis showed:

📑 Reference: Int J Mol Sci, 2024 (link)

• In Weber’s multicenter pain study (2021):

📑 See the full Weber pain study report here → Weber Science Page

Clinical takeaway: IV laser therapy offers a reproducible, non-pharmacological option for managing chronic pain with measurable biomarker improvements.

Next step: Review Weber’s published protocols and consider integrating ILIB into your chronic pain and inflammatory care pathways.

Looking Ahead

In future editions, I’ll share:

• Case studies in oncology support and immune resilience
• Protocol guidance for tPBM in neurodegenerative care
• News from ongoing international collaborations

At Weber Medical, we believe that depth matters. Many light devices stop at the surface, but our CE-approved protocols — intravenous, interstitial, and transcranial — are designed to bring light where it’s needed most. Safely. Precisely. Clinically.

Thank you for joining me in this work. Together, we can expand how light is used in medicine.

Until next time,

Robert Weber, M.Sc.

Founder, Weber Medical Systems

President, International Society for Medical Laser Applications